ArticleCancers2023

BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.

Ahmed M Elshazly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.